Day 1 🚨 #RENALC24
The KEYNOTE-564 trial: first study to do so. However, several important questions remain unresolved. Key among them is determining which patients benefit most from adjuvant therapy and which might not need it at all. #KidneyCancer
The KEYNOTE-564 trial: first study to do so. However, several important questions remain unresolved. Key among them is determining which patients benefit most from adjuvant therapy and which might not need it at all. #KidneyCancer
Day 1🚨 #RENALC24
Dr. Bernadett Szabados
Metastatic RCC
KN-564 trial is significant for demonstrating adjuvant pembrolizumab improves survival in #kidneyCancer
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Register
https://buff.ly/3Z4aEt3
Dr. Bernadett Szabados
Metastatic RCC
KN-564 trial is significant for demonstrating adjuvant pembrolizumab improves survival in #kidneyCancer
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Register
https://buff.ly/3Z4aEt3
November 26, 2024 at 12:59 PM
Everybody can reply
7 likes
Day One of #RENALC24
Dr. Philippe BARTHÉLÉMY
High-risk RCC after nephrectomy & oligometastatic RCC
Risk assessment of post-nephrectomy patients
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
#KidneyCancer
Register:
https://buff.ly/3Z4aEt3
Dr. Philippe BARTHÉLÉMY
High-risk RCC after nephrectomy & oligometastatic RCC
Risk assessment of post-nephrectomy patients
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
#KidneyCancer
Register:
https://buff.ly/3Z4aEt3
November 26, 2024 at 12:51 PM
Everybody can reply
5 reposts
2 quotes
9 likes
Thank you Mirrors of Medicine & dear Colleagues
#PROSCA24 #BLADDR24 & #RENALC24
FINAL STATS with OVER 21 million impression on X
SHOUT OUT TO Our Ambassadors Specially
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@pgrivasmdphd.bsky.social
@achoud72.bsky.social
#PROSCA24 #BLADDR24 & #RENALC24
FINAL STATS with OVER 21 million impression on X
SHOUT OUT TO Our Ambassadors Specially
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@pgrivasmdphd.bsky.social
@achoud72.bsky.social
December 2, 2024 at 2:13 PM
Everybody can reply
4 reposts
6 likes
2 Million Impressions on the first ever #RenalC24
Congratulations to our Collaborators at Mirrors of Medicine
JOIN US TOMORROW for Day One of #BLADDR24
WE ARE @OncoAlert 🚨
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Congratulations to our Collaborators at Mirrors of Medicine
JOIN US TOMORROW for Day One of #BLADDR24
WE ARE @OncoAlert 🚨
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
November 26, 2024 at 5:24 PM
Everybody can reply
4 reposts
1 quotes
11 likes
Day One of #RENALC24
Dr. Philippe BARTHÉLÉMY
Looking ahead: RCC management in 2025
Importance of precision medicine, optimization of combination therapies & need for new biomarkers to improve outcomes.
#KidneyCancer
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
Dr. Philippe BARTHÉLÉMY
Looking ahead: RCC management in 2025
Importance of precision medicine, optimization of combination therapies & need for new biomarkers to improve outcomes.
#KidneyCancer
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
November 26, 2024 at 4:46 PM
Everybody can reply
7 reposts
1 quotes
8 likes
GREAT 1st DAY OF #PROSCA24
Currently going on in Vienna🇦🇹
Perfect way to follow up 2 Amazing meetings in #RENALC24 @ #BLADDR24 w/ OVER 10 million impressions on X ‼️
Kudos to Mirrors of Medicine
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Currently going on in Vienna🇦🇹
Perfect way to follow up 2 Amazing meetings in #RENALC24 @ #BLADDR24 w/ OVER 10 million impressions on X ‼️
Kudos to Mirrors of Medicine
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
November 29, 2024 at 11:01 AM
Everybody can reply
4 reposts
1 quotes
6 likes
Thank you Mirrors of Medicine & dear Colleagues
#PROSCA24 #BLADDR24 & #RENALC24 have just concluded with OVER 20 million impression on X
SHOUT OUT TO Our Ambassadors
Specially
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@pgrivasmdphd.bsky.social
@achoud72.bsky.social
#PROSCA24 #BLADDR24 & #RENALC24 have just concluded with OVER 20 million impression on X
SHOUT OUT TO Our Ambassadors
Specially
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@pgrivasmdphd.bsky.social
@achoud72.bsky.social
November 30, 2024 at 12:33 PM
Everybody can reply
4 reposts
2 quotes
8 likes
Day 1 of #RENALC24
Dr.Pickering
Treatment options in metastatic papillary RCC
#KidneyCancer is diverse, with distinct entities, particularly in non-clear-cell subtypes like papillary
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Dr.Pickering
Treatment options in metastatic papillary RCC
#KidneyCancer is diverse, with distinct entities, particularly in non-clear-cell subtypes like papillary
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
November 26, 2024 at 3:50 PM
Everybody can reply
4 reposts
1 quotes
9 likes
Day 1🚨 #RENALC24
Dr. Bernadett Szabados
Metastatic RCC
KN-564 trial is significant for demonstrating adjuvant pembrolizumab improves survival in #kidneyCancer
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Register
https://buff.ly/3Z4aEt3
Dr. Bernadett Szabados
Metastatic RCC
KN-564 trial is significant for demonstrating adjuvant pembrolizumab improves survival in #kidneyCancer
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Register
https://buff.ly/3Z4aEt3
November 26, 2024 at 12:20 PM
Everybody can reply
4 reposts
1 quotes
7 likes
Day 1 of #RENALC24
Dr. Axel Bex
High-risk RCC after nephrectomy and oligometastatic RCC
To operate or not? Debate on deferred cytoreductive nephrectomy
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Register:
https://buff.ly/3Z4aEt3
Dr. Axel Bex
High-risk RCC after nephrectomy and oligometastatic RCC
To operate or not? Debate on deferred cytoreductive nephrectomy
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Register:
https://buff.ly/3Z4aEt3
November 26, 2024 at 1:50 PM
Everybody can reply
3 reposts
1 quotes
7 likes
Targeted tx for papillary RCC require tailored approaches, as enrichment strategies based solely on histology are insufficient, & selective inhibitors offer better tolerability. In met papillary RCC, VEGF- & MET-directed tx show efficacy, w/cabozantinib being a potential standard of care #RenalC24 🚨
Day 1 of #RENALC24
Dr.Pickering
Treatment options in metastatic papillary RCC
#KidneyCancer is diverse, with distinct entities, particularly in non-clear-cell subtypes like papillary
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Dr.Pickering
Treatment options in metastatic papillary RCC
#KidneyCancer is diverse, with distinct entities, particularly in non-clear-cell subtypes like papillary
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
November 26, 2024 at 5:00 PM
Everybody can reply
7 reposts
1 quotes
17 likes
For metastatic RCC, current combo therapies have led to significant outcome improvements and durable responses. The conclusion highlights the importance of precision medicine, optimization of combination therapies, and the need for new biomarkers to improve patient outcomes
#RenalC24 🚨 #kidneyCancer
#RenalC24 🚨 #kidneyCancer
Day One of #RENALC24
Dr. Philippe BARTHÉLÉMY
Looking ahead: RCC management in 2025
Importance of precision medicine, optimization of combination therapies & need for new biomarkers to improve outcomes.
#KidneyCancer
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
Dr. Philippe BARTHÉLÉMY
Looking ahead: RCC management in 2025
Importance of precision medicine, optimization of combination therapies & need for new biomarkers to improve outcomes.
#KidneyCancer
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
November 26, 2024 at 6:32 PM
Everybody can reply
4 reposts
10 likes
Dr. Barthelemy,
Moving forward, identifying biomarkers like KIM1 and T-effector gene expression signatures could help predict which patients are more likely to benefit from therapy. The need for predictive algorithms to assess efficacy and toxicity is clear #kidneyCancer
#RenalC24 🚨
Moving forward, identifying biomarkers like KIM1 and T-effector gene expression signatures could help predict which patients are more likely to benefit from therapy. The need for predictive algorithms to assess efficacy and toxicity is clear #kidneyCancer
#RenalC24 🚨
Day One of #RENALC24
Dr. Philippe BARTHÉLÉMY
High-risk RCC after nephrectomy & oligometastatic RCC
Risk assessment of post-nephrectomy patients
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
#KidneyCancer
Register:
https://buff.ly/3Z4aEt3
Dr. Philippe BARTHÉLÉMY
High-risk RCC after nephrectomy & oligometastatic RCC
Risk assessment of post-nephrectomy patients
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
#KidneyCancer
Register:
https://buff.ly/3Z4aEt3
November 26, 2024 at 2:12 PM
Everybody can reply
5 reposts
8 likes
Great slides - thanks for sharing. Noted the inclusion and importance of #clinicaltrials for papillary RCC specifically.
Thank you all.
Sincerely, papillary rcc patient #kidneycancer #RenalC24
Thank you all.
Sincerely, papillary rcc patient #kidneycancer #RenalC24
Targeted tx for papillary RCC require tailored approaches, as enrichment strategies based solely on histology are insufficient, & selective inhibitors offer better tolerability. In met papillary RCC, VEGF- & MET-directed tx show efficacy, w/cabozantinib being a potential standard of care #RenalC24 🚨
Day 1 of #RENALC24
Dr.Pickering
Treatment options in metastatic papillary RCC
#KidneyCancer is diverse, with distinct entities, particularly in non-clear-cell subtypes like papillary
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Dr.Pickering
Treatment options in metastatic papillary RCC
#KidneyCancer is diverse, with distinct entities, particularly in non-clear-cell subtypes like papillary
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
November 26, 2024 at 9:56 PM
Everybody can reply
3 reposts
7 likes
Proponents of deferred CN argue a complete pathological response in the 1ry tumor is rare, and even in cases of complete response at metastatic sites, viable tumor cells may remain in the 1ry site. Removing the primary tumor might help eliminate rapidly metastasizing clones
#RenalC24 🚨 #kidneyCancer
#RenalC24 🚨 #kidneyCancer
Day 1 of #RENALC24
Dr. Axel Bex
High-risk RCC after nephrectomy and oligometastatic RCC
To operate or not? Debate on deferred cytoreductive nephrectomy
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Register:
https://buff.ly/3Z4aEt3
Dr. Axel Bex
High-risk RCC after nephrectomy and oligometastatic RCC
To operate or not? Debate on deferred cytoreductive nephrectomy
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Register:
https://buff.ly/3Z4aEt3
November 26, 2024 at 4:14 PM
Everybody can reply
3 reposts
9 likes